PubMed Health⌕ Search

PubMed · 12875350

Understanding and using diagnostic tests.

Abstract

Every diagnostic test causes additional cost if not additional risk. The cost and risk are justified if the test result is likely to change what is done for patients. This includes a diagnostic test that does not alter therapy but provides important prognostic information for the parents. Whether the test result changes therapy depends on: the action threshold (the probability of disease at which the clinician offers the therapy or intervention because it would do more good than harm). the patient's pretest probability of disease. the test performance (measured by LRs, sensitivity, and specificity). For all tests there is an inverse relationship or trade-offbetween sensitivity and specificity. A good diagnostic test is one in which this trade-off is relatively small within the range of sensitivities and specificities that are clinically relevant. When diagnostic tests are used in low-risk subjects (as in screening tests), the performance of the test is critical because missing a significant number of cases is considered unacceptable and subjecting healthy individuals to the repercussions of false-positive test results is also problematic. The decision to introduce a screening program also depends on the availability and cost of screening and diagnostic tests, the potential for testing to cause harm, the prevalence and prognosis of the condition, the availability of effective treatment, and the importance of presymptomatic treatment.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Virginia A Moyer, Kathleen A Kennedy. 2003. Understanding and using diagnostic tests.. https://doi.org/10.1016/s0095-5108(03)00022-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection.

We collected specimens from women who tested positive for Neisseria gonorrhoeae using the Gen-Probe APTIMA Combo 2 (AC2), and we performed confirmatory tests using a nucleic acid amplification test (NAAT) that targets alternate gonococcal nucleic acid sequences. Among 59,664 specimens, 280 (0.47%) had positive results using AC2; 265 of these specimens were tested using the confirmatory NAAT, of which 258 yielded positive results (positive predictive value, 97.4%; 95% confidence interval, 95.1%-98.8%). Routine confirmatory testing of specimens with positive AC2 gonorrhea test results is not indicated.

Diagnostic Tests, Routine↗

Clinical management where medicine meets management. Array of hope.

Routine use of genetic profiling for managing some cancers could soon be a reality. Its wider application in cancer care will require substantial public investment in research and development, IT and setting up a service infrastructure. The first commercial test kits for breast cancer prognosis have already been launched in Europe and the US.

Diagnostic Tests, Routine↗